Solara Active Pharma Q1 FY27: PAT ₹16.3 cr, revenue ₹384 cr

Board meets on July 23 to approve Q1 FY27 numbers

Solara Active Pharma Sciences said its Board of Directors met on July 23, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026 (Q1 FY27). The company also indicated that a press release and earnings presentation for the board meeting would be made available on its website under investor updates. The filing was made under Regulation 30 of the SEBI Listing Regulations. The company’s scrip codes were shown as BSE: 541540 (also referenced: 890202) and NSE: SOLARA. The development matters because Solara has been coming off a volatile FY26, where quarterly profitability improved, but the full year still ended in a loss.

Key Q1 FY27 headline: profit number and what was verified

A raw market alert circulating alongside the board meeting referenced a consolidated net profit of ₹16.3 crore for Q1 FY27, noting the figure was not independently verified in that alert. Separately, the company’s Q1’27 earnings update provided the same profit after tax figure as INR 163 million, which equals ₹16.3 crore, along with revenue and EBITDA details. In the update, Solara described the quarter as a “strong” base business performance with continued growth and profitability. The company also said Q1 FY27 delivered the highest EBITDA and PAT over the last eighteen quarters, as per its presentation.

Q1 FY27 revenue, EBITDA and segment split

In its earnings update dated July 23, 2026, Solara reported overall revenues of INR 3,843 million, which equals ₹384.3 crore, up 20% year-on-year. Overall EBITDA was stated at INR 635 million (₹63.5 crore), up 10% year-on-year. Overall PAT was reported at INR 163 million (₹16.3 crore), up 55% year-on-year, according to the same update. The company also split performance between the base business (excluding ibuprofen) and the ibuprofen business.

Base business (excluding ibuprofen) revenues were INR 3,077 million (₹307.7 crore), up 24% year-on-year, and base business EBITDA was INR 722 million (₹72.2 crore), up 8% year-on-year. For the ibuprofen business, revenues were INR 765 million (₹76.5 crore) and EBITDA was a loss of INR 87 million (₹8.7 crore). The company said EBITDA was marginally impacted by higher input costs linked to geopolitical developments in West Asia.

How Q1 FY27 compares with the prior year quarter and recent quarter

The article context highlighted that Solara had reported a consolidated net profit of ₹10.5 crore in Q1 FY26, forming a direct year-on-year comparison point. It also noted that in Q4 FY26 (quarter ended March 31, 2026), consolidated net profit stood at ₹9.60 crore, recovering from a net loss of ₹2.10 crore in the same period of the previous year. These numbers frame Q1 FY27’s PAT of ₹16.3 crore as an improvement over both Q1 FY26 and Q4 FY26 on an absolute basis, based on figures stated in the provided material.

Full-year FY26 context: quarterly recovery, annual loss

Despite the quarterly improvements reported through FY26, the company’s full fiscal year 2025-26 (FY26) was shown as an overall net loss of ₹7.41 crore. This compared with a marginal net profit of ₹0.54 crore in the preceding fiscal year, as stated in the article data. The combination of quarterly profits but a full-year loss indicates FY26 included periods of weaker performance that outweighed later-quarter recovery. That context is relevant when reading Q1 FY27’s profitability because the company is still building consistency across quarters.

What the quarterly operating snapshot shows (FY26 trend)

The provided quarterly table (figures in ₹ crore) showed net sales rising from ₹273.01 crore in Mar 2025 to ₹319.15 crore in Jun 2025, and later reaching ₹387.29 crore in Mar 2026. Over the same sequence, operating profit moved from ₹42.59 crore (Mar 2025) to ₹57.03 crore (Jun 2025), and ₹57.55 crore (Mar 2026). The table also showed interest costs in the ₹20-29 crore range across those quarters and depreciation in the ₹23-26 crore range. Profit after tax in that table for Jun 2025 was ₹10.53 crore, and for Mar 2026 was ₹9.73 crore.

Table: Q1 FY27 performance snapshot (as per earnings update)

Market snapshot and price references shown in the material

The material included a market snapshot showing Solara at ₹585.40, up ₹16.50 (2.90%), timestamped “NSE: 13 Jul 4:00 PM”. It also showed another reference stating, “The current price of Solara Active Pharma Sciences Ltd is ₹ 570.15.” A separate line showed “Current Price ₹ 472,” which appears as an additional displayed metric in the provided text. Since these are multiple price references from the same compiled data, readers typically rely on the latest exchange quote at the time they check.

Capital actions and investor communications mentioned

The article data also referenced a corporate action from April 2026, when Solara issued a second and final call notice for payment of ₹112.50 per partly paid-up rights equity share to complete fund-raising activities. Separately, a table snippet in the material referenced a proposal to consider and approve making a first call on 1,19,98,755 partly paid-up equity shares (dated 26-Mar-2025). These items indicate the company has been using equity-related processes tied to partly paid-up shares over the recent period.

Conference call and next steps for investors

Solara’s earnings communication also mentioned an earnings conference call scheduled for Friday, July 23, 2026 at 16:00 hours, with dial-in numbers provided. The company said the press release and earnings presentation for the board meeting would be made available on its website and via the exchange filing portals. With Q1 FY27 financials approved at the board meeting and the earnings update providing revenue, EBITDA, and PAT, the next practical step for investors is to track the detailed filings (standalone and consolidated) on BSE and NSE for complete line items and disclosures.

Conclusion

Solara Active Pharma’s July 23, 2026 board meeting cleared Q1 FY27 financial results, with the company reporting revenue of ₹384.3 crore, EBITDA of ₹63.5 crore, and PAT of ₹16.3 crore in its earnings update. The quarter builds on a period where Solara reported profits in Q1 FY26 and Q4 FY26 but ended FY26 with a net loss of ₹7.41 crore. Investors will likely focus on the detailed exchange filings and management commentary from the scheduled conference call for more colour on segment profitability, input cost pressures, and the ibuprofen business performance.